Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Clin Cancer Res. 2019 Sep 12;25(23):7089–7097. doi: 10.1158/1078-0432.CCR-19-2004

Fig. 4. Class 2 mutations can cause secondary resistance to EGFR inhibitors.

Fig. 4.

(A) Timeline of patient’s treatment history, (B) Representative images from PET/CT showing biopsy-proven, hypermetabolic metastatic thoracic lymphadenopathy at the start of FOLFIRI/cetuximab treatment and after one year of treatment, (C) Representative MRI image showing new cerebellar metastasis, (D) Schema of the MKRN1-BRAF fusion identified on sequencing the cerebellar metastasis, (E) Growth curve of mice bearing the PDX with MKRN1-BRAF fusion treated with vehicle or cetuximab. Five mice were treated in each group and standard deviations are indicated with error bars.